Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bert Vander Cruyssen

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 10, 2021
Circulating calprotectin as biomarker in neutrophil-related inflammation: Pre-analytical recommendations and reference values according to sample typeMarnix Mylemans, Louis Nevejan, Stefanie Van Den Bremt, et al.
The Journal of Rheumatology|October 11, 2007
Decrease of disease activity under ineffective therapy in DMARD-naive patients with early rheumatoid arthritis: role of antibody profiles and carriage of the HLA shared epitope in predicting decrease of disease activityBert Vander Cruyssen, André M M Miltenburg, Filip Van den Bosch, et al.
Arthritis Research & Therapy|July 25, 2006
Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assaysBert Vander Cruyssen, Tineke Cantaert, Leonor Nogueira, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2008
A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritisPieter Dewint, Valerie Gossye, Karolien De Bosscher, et al.
Annals of the Rheumatic Diseases|March 16, 2011
Predicting the outcome of ankylosing spondylitis therapyNathan Vastesaeger, Désirée van der Heijde, Robert D Inman, et al.
Annals of the Rheumatic Diseases|October 5, 2018
Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trialMargreet Kloppenburg, Roberta Ramonda, Klaus Bobacz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2007
A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific mannerKen Coppieters, Katrien Van Beneden, Peggy Jacques, et al.
Arthritis Research & Therapy|September 19, 2006
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activityBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Journal of Thrombosis and Haemostasis : JTH|May 18, 2025
Multicenter study to improve clinical interpretation of anticardiolipin and anti-β2-glycoprotein I antibody test results for diagnosis of antiphospholipid syndromeLieve Van Hoovels, Silvia Piantoni, Els Bailleul, et al.
Arthritis Research & Therapy|October 7, 2005
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatmentBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 10, 2021
Circulating calprotectin as biomarker in neutrophil-related inflammation: Pre-analytical recommendations and reference values according to sample typeMarnix Mylemans, Louis Nevejan, Stefanie Van Den Bremt, et al.
The Journal of Rheumatology|October 11, 2007
Decrease of disease activity under ineffective therapy in DMARD-naive patients with early rheumatoid arthritis: role of antibody profiles and carriage of the HLA shared epitope in predicting decrease of disease activityBert Vander Cruyssen, André M M Miltenburg, Filip Van den Bosch, et al.
Arthritis Research & Therapy|July 25, 2006
Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assaysBert Vander Cruyssen, Tineke Cantaert, Leonor Nogueira, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2008
A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritisPieter Dewint, Valerie Gossye, Karolien De Bosscher, et al.
Annals of the Rheumatic Diseases|March 16, 2011
Predicting the outcome of ankylosing spondylitis therapyNathan Vastesaeger, Désirée van der Heijde, Robert D Inman, et al.
Annals of the Rheumatic Diseases|October 5, 2018
Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trialMargreet Kloppenburg, Roberta Ramonda, Klaus Bobacz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2007
A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific mannerKen Coppieters, Katrien Van Beneden, Peggy Jacques, et al.
Arthritis Research & Therapy|September 19, 2006
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activityBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Journal of Thrombosis and Haemostasis : JTH|May 18, 2025
Multicenter study to improve clinical interpretation of anticardiolipin and anti-β2-glycoprotein I antibody test results for diagnosis of antiphospholipid syndromeLieve Van Hoovels, Silvia Piantoni, Els Bailleul, et al.
Arthritis Research & Therapy|October 7, 2005
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatmentBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Pageof 4